(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2020 (15.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/210386 A1

(51) International Patent Classification:
C07K 16/10 (2006.01) *C07K 16/46* (2006.01)
C07K 16/28 (2006.01) *A61P 31/18* (2006.01)

(21) International Application Number:
PCT/US2020/027313

(22) International Filing Date:
08 April 2020 (08.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/831,415 09 April 2019 (09.04.2019) US
19306312.0 08 October 2019 (08.10.2019) EP

(71) Applicants: **SANOFI** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR). **THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; c/o National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852 (US).

(72) Inventors: **ASOKAN, Mangaiarkarasi**; c/o National Institutes of Health, BG 40 RM 4610, 40 Convent Drive, Bethesda, Maryland 20814 (US). **BEIL, Christian**; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BENINGA, Jochen**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BIRKENFELD, Joerg**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **CONNORS, Mark**; c/o National Institutes of Health, BG 10 RM 11B07C, 10 Center Drive, Bethesda, Maryland 20814 (US). **KOUP, Richard A.**; c/o National Institutes of Health, BG 40 RM 3502, 40 Convent Drive, Bethesda, Maryland 20814 (US). **KWON, Young Do**; c/o National Institutes of Health, BG 40 RM 46078, 40 Convent Drive, Bethesda, Maryland 20814 (US). **KWONG, Peter D.**; c/o National Institutes of Health, BG 40 RM 4508, 40 Convent Drive, Bethesda,

WO 2020/210386 A1

(54) Title: TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING THE CROSS-OVER-DUAL-VARIABLE DOMAIN (CODV) FORMAT FOR TREATMENT OF HIV INFECTION



FIG. 1

(57) Abstract: Using the Cross-Over-Dual-Variable Domain (CODv) format, the present disclosure relates to compositions comprising trispecific and/ or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein a second pair of polypeptides possess a single variable domain. Also provided herein are methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins for the treatment and/or prevention of HIV/AIDS.

[Continued on next page]

Maryland 20814 (US). **LIU, Qingbo**; c/o National Institutes of Health, BG 10 RM 6A11, 10 Center Drive, Bethesda, Maryland 20814 (US). **LUSSO, Paolo**; c/o National Institutes of Health, BG 10 RM 6A11, 10 Center Drive, Bethesda, Maryland 20814 (US). **MASCOLA, John R.**; c/o National Institutes of Health, BG 40 RM 4502, 40 Convent Drive, Bethesda, Maryland 20814 (US). **NABEL, Gary J.**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **PEGU, Amarendra**; c/o National Institutes of Health, BG 40 RM 4612B, 40 Convent Drive, Bethesda, Maryland 20814 (US). **RAO, Ercole**; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WEI, Ronnie**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **XU, Ling**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US). **YANG, Zhi-Yong**; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-525, Bridgewater, New Jersey 08807 (US).

(74) **Agent: JONES, Kevin** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*